Compare · GILD vs SCNI
GILD vs SCNI
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Scinai Immunotherapeutics Ltd. (SCNI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SCNI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $166.72B, about 133122.9x SCNI ($1.3M).
- Over the past year, GILD is up 24.0% and SCNI is down 88.8% - GILD leads by 112.8 points.
- GILD has hit the wire 4 times in the past 4 weeks while SCNI has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for SCNI).
- Company
- Gilead Sciences Inc.
- Scinai Immunotherapeutics Ltd.
- Price
- $134.23-1.50%
- $0.24-7.73%
- Market cap
- $166.72B
- $1.3M
- 1M return
- +5.49%
- -27.96%
- 1Y return
- +23.95%
- -88.84%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2015
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Latest SCNI
- Director Germain Mark was granted 120,000,000 units of Ordinary Shares (SEC Form 4)
- Chief Executive Officer Reichman Amir was granted 400,000,000 units of Ordinary Shares, increasing direct ownership by 128% to 711,637,600 units (SEC Form 4)
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
- SEC Form EFFECT filed by Scinai Immunotherapeutics Ltd.
- SEC Form 424B3 filed by Scinai Immunotherapeutics Ltd.
- Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe